Conduit Pharmaceuticals Inc. (CDT)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. David Joszef Tapolczay | CEO & Director | 419.8k | -- | 1959 |
| Mr. James Bligh | Interim CFO & Director | 533.35k | -- | 1988 |
| Dr. Joanne M. Holland | Chief Scientific Officer | -- | -- | 1975 |
| Mr. Bill Begien | Senior VP of Investor Relations | -- | -- | -- |
Conduit Pharmaceuticals Inc.
- Sector:?
- Healthcare
- Industry:? Biotechnology
- Full Time Employees:?
- 7
Description
Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
September 16, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission